These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 20818645)

  • 21. Sequential designs for phase III clinical trials incorporating treatment selection.
    Stallard N; Todd S
    Stat Med; 2003 Mar; 22(5):689-703. PubMed ID: 12587100
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An adjustment for patient heterogeneity in the design of two-stage phase II trials.
    Sposto R; Gaynon PS
    Stat Med; 2009 Sep; 28(20):2566-79. PubMed ID: 19521973
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Estimating cumulative probabilities from incomplete longitudinal binary responses with application to HIV vaccine trials.
    Hudgens MG
    Stat Med; 2003 Feb; 22(3):463-79. PubMed ID: 12529875
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Conservative sample size estimation in nonparametrics.
    De Martini D
    J Biopharm Stat; 2011 Jan; 21(1):24-41. PubMed ID: 21191852
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Parameter estimation following an adaptive treatment selection trial design.
    Luo X; Wu SS; Xiong J
    Biom J; 2010 Dec; 52(6):823-35. PubMed ID: 21154898
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Conditional and unconditional confidence intervals following a group sequential test.
    Fan X; DeMets DL
    J Biopharm Stat; 2006; 16(1):107-22. PubMed ID: 16440840
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bayesian bivariate meta-analysis of diagnostic test studies using integrated nested Laplace approximations.
    Paul M; Riebler A; Bachmann LM; Rue H; Held L
    Stat Med; 2010 May; 29(12):1325-39. PubMed ID: 20101670
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Confidence intervals of effect size in randomized comparative parallel-group studies.
    Wu J; Jiang G; Wei W
    Stat Med; 2006 Feb; 25(4):639-51. PubMed ID: 16158411
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design and analysis of phase I clinical trials.
    Storer BE
    Biometrics; 1989 Sep; 45(3):925-37. PubMed ID: 2790129
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A likelihood approach to meta-analysis with random effects.
    Hardy RJ; Thompson SG
    Stat Med; 1996 Mar; 15(6):619-29. PubMed ID: 8731004
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A stepwise approach to justify phase III randomized clinical trials and enhance the likelihood of a positive result.
    McAuley DF; O'kane C; Griffiths MJ
    Crit Care Med; 2010 Oct; 38(10 Suppl):S523-7. PubMed ID: 21164392
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Confidence intervals for correlated proportion differences from paired data in a two-arm randomised clinical trial.
    Pei Y; Tang ML; Wong WK; Guo J
    Stat Methods Med Res; 2012 Apr; 21(2):167-87. PubMed ID: 20442192
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design of adaptive two-stage double-arm clinical trials for dichotomous variables.
    Jiang Z; Xue F; Li C; Wang L; Cai H; Zhang C; Xia J
    Contemp Clin Trials; 2010 May; 31(3):242-50. PubMed ID: 20172053
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discounting phase 2 results when planning phase 3 clinical trials.
    Kirby S; Burke J; Chuang-Stein C; Sin C
    Pharm Stat; 2012; 11(5):373-85. PubMed ID: 22641524
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Statistical inference for extended or shortened phase II studies based on Simon's two-stage designs.
    Zhao J; Yu M; Feng XP
    BMC Med Res Methodol; 2015 Jun; 15():48. PubMed ID: 26048655
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bayesian perspectives for epidemiologic research: III. Bias analysis via missing-data methods.
    Greenland S
    Int J Epidemiol; 2009 Dec; 38(6):1662-73. PubMed ID: 19744933
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Methodological approaches of clinical studies with targeted therapies].
    Penel N; Saleron J; Lansiaux A; Clisant S; Adenis A; Fournier C; Duhamel A; Bonneterre J
    Bull Cancer; 2008 Feb; 95(2):185-90. PubMed ID: 18304903
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Active-control trials with binary data: a comparison of methods for testing superiority or non-inferiority using the odds ratio.
    Siqueira AL; Whitehead A; Todd S
    Stat Med; 2008 Feb; 27(3):353-70. PubMed ID: 17628041
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessing the success probability of a Phase III clinical trial based on Phase II data.
    Su Z
    Contemp Clin Trials; 2010 Nov; 31(6):620-3. PubMed ID: 20713180
    [TBL] [Abstract][Full Text] [Related]  

  • 40. "Sufficient life expectancy": an amazing inclusion criterion in cancer phase II-III trials.
    Penel N; Clisant S; Lefebvre JL; Adenis A
    J Clin Oncol; 2009 Sep; 27(26):e105. PubMed ID: 19667257
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.